University of South Alabama | Surgery Department

Research site

(Unclaimed)

Location

2451 University Hospital Drive, Mobile, Alabama, United States of America

Site insights

Top conditions

Top treatments

Gemcitabine

Elagolix

Carboplatin

Paclitaxel

Estradiol

Acetaminophen

Veliparib

ABBV-951

ARQ 501

Dexlansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 101 total trials

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1)

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling

Non-Small Cell Lung Cancer

Drug: Durvalumab

Drug: Entrectinib

A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube...

Enrolling

Erosive Esophagitis

Drug: Dexlansoprazole

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube...

Enrolling

Gastroesophageal Reflux Disease (GERD)

Drug: Dexlansoprazole

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizuma...

Enrolling

Relapsing-remitting Multiple Sclerosis (RRMS)

Drug: Ocrelizumab (EU)

Drug: Ocrelizumab (US)

Multicenter Single-arm Trial to Investigate Clinical Outcomes When Cohealyx™ is Used for Full Thickness Wounds (Cohealyx I)

The goal of this study is to look at clinical outcomes when Cohealyx Collagen Matrix is used to treat full thickness wounds after surgical excision i...

Enrolling

Surgical Wound

Full Thickness Wounds

Device: Cohealyx

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in...

Active, not recruiting

Non-Small Cell Lung Carcinoma

Nonsmall Cell Lung Cancer

Drug: efineptakin alfa

Drug: Atezolizumab

Randomized Study of the pdSTIM™ System (Phrenic Nerve to Diaphragm STIMulation) in Failure to Wean Mechanically Ventilated Patients (ReInvigorate)

This prospective, multi-center, randomized, controlled clinical trial is being conducted to evaluate the safety and efficacy of the pdSTIM System to...

Enrolling

Ventilator Induced Diaphragm Dysfunction

Device: pdSTIM System Therapy

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for teliso...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Telisotuzumab vedotin

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot fr...

Active, not recruiting

Parkinson's Disease (PD)

Drug: ABBV-951

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or a...

Enrolling

HSV Infection

Drug: Investigator's choice

Drug: Pritelivir